From 2007 to 2015 the absolute number of newly diagnosed cases of cervical cancer (CC) in the Moscow region (MR) increased from 594 to 785; the incidence rate per 100,000 in MR for the last 14 years increased from 7.9 in 2002 to 19.5 in 2015, and mortality rate during the 1st year of follow-up exceeds 12%. The program of vaccine prophylaxis of HPV-associated oncological diseases with quadrivalent vaccine in 12 to 13-year-old girls with a 0-2-6 month regimen has been conducted in MO (18 municipal districts) since 2008.
To conduct the efficacy analysis of the vaccine prophylaxis program.
The incidence rate of HPV-associated diseases in girls and women in 2009 to 2015 and the vaccination safety with the use of the specially designed register were studied.
20,000 female adolescents were vaccinated during the 9-year program. The decrease in the incidence rate of anogenital condylomas (AC) was registered during the study period: the general incidence rate decreased from 127.2 to 24.7, the incidence rate per 100,000 children – from 63.3 to 11.9, and the incidence rate per 100,000 girls who reside in districts covered with vaccine prophylaxis - from 14.2 to 6.1 per 100,000; the decrease of the incidence rate of AC for the study period in the whole female population from 56.7 to 20.2 (per 100,000) was also reported. A positive trend in the decrease of CC case detection in the 15-24 age group from 0.3 to 0.1 (the rate of the detected CC cases among women of all ages) was registered in districts covered by vaccination; no CC cases in young women were registered. According to the register data, no serious adverse events were reported for the vaccination period; some vaccinated patients became pregnant and delivered healthy children.
The results of the vaccine prophylaxis program of HPV-associated diseases conducted in MR have demonstrated the safety and efficacy of vaccine prophylaxis using a quadrivalent vaccine in decreasing the incidence rates of anogenital condylomas in girls and cervical cancer in young women.